tm logo
IMPACT
Dead/Abandoned
ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE

failure to respond or late response

on 15 Jul 2020

Last Applicant/ Owned by

33 Technology Drive

Warren

NJ

07059

Serial Number

88336123 filed on 12th Mar 2019

Registration Number

N/A

Correspondent Address

Camille M. Miller

Cozen O'Connor

One Liberty Place

1650 Market Street, Suite 2800

Philadelphia PA 19103

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

IMPACT

Cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, placental tissue for use in scientific, laboratory and medical research; bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; human amniotic membrane aRead More

Classification Information


Class [001]
Chemical Products


Cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, placental tissue for use in scientific, laboratory and medical research; bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; human amniotic membrane and human chorionic membrane for use in scientific, laboratory and medical research; human collagen and extracellular matrix compositions for use in scientific, laboratory and medical research; biological preparations for use in scientific, laboratory and medical research; biological products for use in scientific, laboratory and medical research, namely, placental-derived natural killer cells

Class [005]
Pharmaceutical Products


Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, umbilical cord cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological preparations for medical use, including for the treatment of cancer and other diseases, namely, auto-immune diseases, inflammatory diseases, Crohn's Disease and Multiple Myeloma; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; cells and biological tissue intended for hair restoration, namely, cells and biological preparations derived from blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen

Mark Details


Serial Number

No 88336123

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 450869/CLTY-

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
15th Jul 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
15th Jul 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
02th Jan 2020NOTIFICATION OF FINAL REFUSAL EMAILED
02th Jan 2020FINAL REFUSAL E-MAILED
02th Jan 2020FINAL REFUSAL WRITTEN
06th Dec 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
06th Dec 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
06th Dec 2019TEAS/EMAIL CORRESPONDENCE ENTERED
28th Jun 2019NON-FINAL ACTION WRITTEN
28th Jun 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED